TrialJournal of neurovirology2019

Similar neurocognitive outcomes after 48 weeks in HIV-1-infected participants randomized to continue tenofovir/emtricitabine + atazanavir/ritonavir or simplify to abacavir/lamivudine + atazanavir.

Kevin Robertson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.